Lupin Gets Namenda License In Forest Settlement

By Melissa Lipman

Law360, New York (December 22, 2009, 4:23 PM ET) -- Lupin Ltd. has received a license to begin selling a generic version of Forest Laboratories Inc.'s Namenda about four months before a patent for the lucrative Alzheimer's drug expires, as part of a settlement between the two companies, the Indian pharmaceutical maker said Monday.

Under the terms of the deal — which resolves all pending Hatch-Waxman Act litigation between the two over the drug — Lupin will have a license under the required patents to launch its generic memantine tablets in January 2015 or earlier in...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles